tert-butyl (5-carboxy-4-chloro-1,3-thiazol-2-yl)carbamate | 612541-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl (5-carboxy-4-chloro-1,3-thiazol-2-yl)carbamate
• 英文别名: 2-[(tert-butoxycarbonyl)amino]-4-chlorothiazole-5-carboxylic acid；2-Amino-4-chloro-1,3-thiazole-5-carboxylic acid, 2-BOC protected；4-chloro-2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazole-5-carboxylic acid
• CAS: 612541-07-8
• 化学式: C₉H₁₁ClN₂O₄S
• 分子量: 278.716
• InChiKey: NBTRAUIPMWUAHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (5-carboxy-4-chloro-1,3-thiazol-2-yl)carbamate 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.5h， 生成 tert-butyl [4-chloro-5-(1-hydroxy-1-methylethyl)-1,3-thiazol-2-yl]carbamate
  参考文献：
  名称：

  Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides

  摘要：

  A random high-throughput screening (HTS) program to discover novel normucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out with MT-4 cells against a nevirapine-resistant virus, HIV-1(IIIB-R). The primary hit, a thiazolidene-benzenesulfonamide derivative, possessed good activity. A systematic modification program examining various substituents at the 3-, 4-, and 5-positions on the thiazole ring afforded compounds with enhanced anti-HIV-1 and reverse transcriptase (RT) inhibitory activities. These results confirm the important role of the substituents at these positions and the thiazolidenebenzenesulfonamide motif as a valuable lead series for the next generation NNRTIs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.08.050
• 作为产物：
  描述：

  2-甲基-2-丙基(4-氯-5-甲酰基-1,3-噻唑-2-基)氨基甲酸酯 在 sodium chlorite 、 potassium dihydrogenphosphate 、 2-甲基-2-丁烯 作用下， 以 水 、 叔丁醇 为溶剂， 反应 6.0h， 生成 tert-butyl (5-carboxy-4-chloro-1,3-thiazol-2-yl)carbamate
  参考文献：
  名称：

  Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides

  摘要：

  A random high-throughput screening (HTS) program to discover novel normucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out with MT-4 cells against a nevirapine-resistant virus, HIV-1(IIIB-R). The primary hit, a thiazolidene-benzenesulfonamide derivative, possessed good activity. A systematic modification program examining various substituents at the 3-, 4-, and 5-positions on the thiazole ring afforded compounds with enhanced anti-HIV-1 and reverse transcriptase (RT) inhibitory activities. These results confirm the important role of the substituents at these positions and the thiazolidenebenzenesulfonamide motif as a valuable lead series for the next generation NNRTIs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.08.050

文献信息

• COMPOUNDS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150152112A1

  公开（公告）日：2015-06-04

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式（I）的化合物，它们的盐和N-氧化物，以及它们的溶剂化物和前药（其中字符如描述中所定义）。一般式（I）的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓性疾病方面非常有用。
• PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP3290413A1

  公开（公告）日：2018-03-07

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式(I)化合物、其盐类和N-氧化物，以及其溶解物和原药（其中特征如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，因此可用于预防和/或治疗血栓栓塞性疾病。
• Pyrimidinone and its derivatives inhibiting factor XIa
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10717738B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式(I)化合物、其盐类和N-氧化物，以及其溶解物和原药（其中特征如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，因此可用于预防和/或治疗血栓栓塞性疾病。
• US9732085B2
  申请人：——

  公开号：US9732085B2

  公开（公告）日：2017-08-15
• WO2023/131690
  申请人：——

  公开号：——

  公开（公告）日：——